About Tumor Mutational Burden
Tumor mutational burden (TMB) is a biomarker that measures the number of somatic mutations present in a cancer patient’s tumor and is quantified as mutations per megabase (mut/Mb). This metric can be used in order to stratify patients for the best treatment choice and support the thriving development of new immunotherapy combinations. Another key immunotherapy biomarker is the microsatellite instability (MSI), which is caused by failure of the DNA mismatch repair system.
With German DAkkS ISO 15189 and American CAP/CLIA accreditation, CeGaT can offer quality assured TMB and MSI evaluation for your clinical and research study. Different options are available, depending on your needs and the availability of patient material.
Start Your Project Now
We are happy to discuss sequencing options and find a solution specifically tailored to your clinical study or research project.
You help us by specifying sample information including starting material, number of samples, preferred library prep option and required bioinformatics.
Turnaround time
Sequencing data are delivered within 5 – 10 working days.
A fast track option is available upon request.
Delivery
Your sequencing data will be available for download from one of our servers (FTAPI or SFTP). Upon request, as well as for large sample batches, data can also be delivered via external hard drive or uploaded to your own server.
Storage
The original samples will be stored at CeGaT for one week after data delivery.
Data will be irrevocably deleted after 5 months.
Bioinformatics
Raw sequencing data are automatically processed in order to facilitate immediate genetic evaluation. Included in delivery are demultiplexed, and adapter trimmed FastQ files.
Further options for bioinformatic analyses are available depending on the selected product:
- Tumor Mutational Burden (TMB)
- Microsatellite Instability status (MSI)
- Alignment of trimmed sequencing data (BAM format)
- Calling and annotation of SNVs (hg19, mm10)
- Calling and annotation InDel
- Large homozygous deletions calling
- Fusion and splice variants*
*based on TSO500 RNA analysis
Technical Information
At CeGaT, paired-end sequencing (2x100bp) is performed using the state-of-the-art Illumina NovaSeq6000 Sequencing System.
If customers require sequencing parameters other than those presented in our product portfolio, please let us know! We can provide further solutions.
Explore our TMB product portfolio
TIO Panel
Sequencing panel
Somatic Tumor Panel (CeGaT GmbH)
Gene panel size (Mb)
2.2
Number of analyzed genes
>700
Analysis of tumor and normal tissue
yes
Selection of our bioinformatic options
TMB, MSI, alignment, variant calling (SNVs/InDels), annotation and filtering
Based on the CeGaT bioinformatic pipeline
TIO Exome
Sequencing panel
Whole exome sequencing (Twist Bioscience)
Gene panel size (Mb)
37
Number of analyzed genes
~ 20,000
Analysis of tumor and normal tissue
yes
Selection of our bioinformatic options
TMB, MSI, alignment, variant calling (SNVs/InDels), annotation and filtering
Based on the CeGaT bioinformatic pipeline
TSO500
Sequencing panel
TruSight Oncology 500* (Illumina)
Gene panel size (Mb)
1.94
Number of analyzed genes
523
Analysis of tumor and normal tissue
no
Selection of our bioinformatic options
TMB, MSI, alignment, variant calling (SNVs/InDels), annotation and filtering
Based on the TSO500 (Illumina) bioinformatic pipeline
TIO: Tumor Immuno-Oncology; *additional analysis of fusion and splice variants available using the TruSight Tumor 170 (Illumina) – RNA panel
Starting material: high-molecular weight DNA, or fragmented DNA (FFPE)
Tumor Mutational Burden and Other Biomarkers Help to Assess the Efficacy of Immunotherapies
